November 19, 2018
CEO Roundtable on Cancer Presents Dr. Charles A. Sanders Life Sciences Award to Jean Becker, Ken Lee and Phil Porter
November 13, 2018
Ribometrix raises $30M to drug upstream RNA with small molecules
November 13, 2018
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
October 25, 2018
Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections
October 25, 2018
Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer
October 22, 2018
G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
July 9, 2018
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
July 09, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel.
April 18, 2018
Standard Bariatrics closes Series A round of financing
April 18, 2018 — CINCINNATI, OH — Standard Bariatrics, Inc., an innovator of bariatric surgical devices, has raised a Series A round of financing. RiverVest Venture Partners led the round with participation from Hatteras Venture Partners, Queen City Angels/QCA First Fund V, Emergent Medical Partners, Accelerant Fund and North Coast Angels. The size of the round is undisclosed.
March 20, 2018
Elligo Health Research Raises $16M to Improve Access to Clinical Trials
March 20, 2018 — AUSTIN, TX (BUSINESS WIRE) — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.
March 13, 2018
Wildflower Health Receives $8 Million Capital Investment in Funding Round Led by Health Enterprise Partners
March 07, 2018 — SAN FRANCISCO (PRWEB) — Wildflower Health today announced it has secured $8 million in capital investment to advance its mission of growing healthy families. The funding round was led by Health Enterprise Partners, a growth equity firm specializing in healthcare services and information technology whose investors include some of the largest health systems and health plans across the country.